$argenx SE(ARGX.US)$ Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering. Unexpectedly Strong Impact of Corticosteroids The primary setback was the ...
72840290 : you dont pump much do you @Nasser09
Jaguar8 72840290:
Jaguar8 72840290: Spotted huh?
NASSER09OP 72840290: I have another App